Recombinant Human CYP2C9 Protein，His

CYP2C9 is a critical enzyme belonging to the cytochrome P450 superfamily, primarily responsible for the metabolism of various clinically significant drugs, including anticoagulants, nonsteroidal anti-inflammatory drugs, and anticonvulsants. Variations in the CYP2C9 gene can lead to polymorphisms that affect enzyme activity, resulting in altered drug clearance and varying patient responses to medications. This variability can influence therapeutic outcomes and increase the risk of adverse drug reactions, making CYP2C9 an important focus in pharmacogenetic research. The expression of recombinant CYP2C9 proteins provides a valuable tool for studying enzyme kinetics, substrate specificity, and drug interactions in vitro. The use of recombinant technology allows for the production of isoforms with specific mutations, enabling a deeper understanding of how genetic variants impact enzyme function. Additionally, insights gained from CYP2C9 research have implications for personalized medicine, allowing healthcare providers to tailor drug therapies based on a patient’s genetic profile, thus optimizing efficacy and minimizing the risk of toxicity. Given the rising emphasis on precision medicine, studies surrounding CYP2C9 recombinant proteins are increasingly relevant, as they pave the way for improved drug development and individualized treatment strategies that can significantly enhance patient care.